The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo

被引：0
|
作者：
Niessner, H. [1 ]
Forschner, A. [1 ]
Schmitz, J. [2 ]
Schmid, A. [2 ]
Calaminus, C. [2 ]
Sinnberg, T. [1 ]
Tabatabai, G. [3 ]
Quintanilla-Fend, L. [4 ]
Pichler, B. J. [2 ]
Garbe, C. [1 ]
Meier, F. [1 ]
机构：
[1] Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Dept Preclin Imaging & Radiopharm, D-72076 Tubingen, Germany
[3] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland
[4] Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany
来源：
EXPERIMENTAL DERMATOLOGY | 2014年 / 23卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E43 / E43
页数：1
相关论文
共 50 条
  • [31] Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study.
    Heudel, Pierre-Etienne
    Fabbro, Michel
    Roemer-Becuwe, Celia
    Treilleux, Isabelle
    Kaminsky, Marie-Christine
    Arnaud, Antoine
    Joly, Florence
    Forestier, Sophie Roche
    Herve, Robert
    Ray-Coquard, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
    McRee, Autumn J.
    Sanoff, Hanna K.
    Carlson, Cheryl
    Ivanova, Anastasia
    O'Neil, Bert H.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1225 - 1231
  • [33] Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells
    Wang, Lei
    Ning, Jianfang
    Wakimoto, Hiroaki
    Wu, Shulin
    Wu, Chin-lee
    Humphrey, Melissa R.
    Rabkin, Samuel D.
    Martuza, Robert L.
    MOLECULAR THERAPY-ONCOLYTICS, 2019, 13 : 58 - 66
  • [34] A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors
    Autumn J. McRee
    Hanna K. Sanoff
    Cheryl Carlson
    Anastasia Ivanova
    Bert H. O’Neil
    Investigational New Drugs, 2015, 33 : 1225 - 1231
  • [35] Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib
    Serova, M.
    Raballand, A.
    Dos Santos, C.
    Riveiro, E.
    Raymond, E.
    Faivre, S.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 113 - 113
  • [36] The Novel PI3K Kinase Inhibitor NVP-BKM120 Shows in Vitro and in Vivo Efficacy in Follicular Lymphoma by Disrupting Microenvironment Survival Signaling
    Matas-Cespedes, A.
    Rodriguez, V.
    Roue, G.
    Campo, E.
    Lopez-Guillermo, A.
    Colomer, D.
    Perez-Galan, P.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S190 - S190
  • [37] Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics
    Azaro, A.
    Rodon, J.
    Vansteenkiste, J. F.
    Ando, Y.
    Doi, T.
    Mills, D.
    Sarr, C.
    Di Tomaso, E.
    Massacesi, C.
    Naumann, R. W.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S186 - S186
  • [38] Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)
    Saura, C.
    Burris, H.
    Arteaga, C. L.
    Mayer, I.
    Germa, C.
    Fretault, N.
    Sternberg, D.
    Trandafir, L.
    Massacesi, C.
    Rodon, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S96 - S96
  • [39] Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120
    Bashash, Davood
    Delshad, Mahda
    Riyahi, Niknam
    Safaroghli-Azar, Ava
    Pourbagheri-Sigaroodi, Atieh B.
    Momeny, Majid
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 841 : 10 - 18
  • [40] BKM120 and BYL719 (PI3K inhibitors) sensitize estrogen receptor positive breast cancer cells to tamoxifen
    Chen, I-Chun
    Gao, Ming
    Hsiao, Lii-Ping
    Huang, Yi-Wen
    Yu, Huei-Chieh
    Yeh, Ling-Chiun
    Cheng, Ann-Lii
    Lu, Yen-Shen
    CANCER RESEARCH, 2015, 75
12345